EA200100936A1 - Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов - Google Patents

Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов

Info

Publication number
EA200100936A1
EA200100936A1 EA200100936A EA200100936A EA200100936A1 EA 200100936 A1 EA200100936 A1 EA 200100936A1 EA 200100936 A EA200100936 A EA 200100936A EA 200100936 A EA200100936 A EA 200100936A EA 200100936 A1 EA200100936 A1 EA 200100936A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptors
compositions
methods
inhibitors
antagonists
Prior art date
Application number
EA200100936A
Other languages
English (en)
Inventor
Пол Д. Рубин
Тимоти Дж. Барберич
Original Assignee
Сепракор Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сепракор Инк. filed Critical Сепракор Инк.
Publication of EA200100936A1 publication Critical patent/EA200100936A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Настоящее изобретение относится к способам и композициям для профилактики, лечения и возможности справляться с нарушениями желудочно-кишечного тракта или их симптомами с использованием двух или более агентов или соединений, которые обеспечивают трехсайтное действие на 5-НТ-рецепторы, на 5-НТ-рецепторы и, по меньшей мере, на один из антагонистов Н-рецепторов и ингибиторов протонных насосов.Отчет о международном поиске был опубликован 2001.02.01.
EA200100936A 1999-03-02 2000-03-01 Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов EA200100936A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12239499P 1999-03-02 1999-03-02
PCT/US2000/005166 WO2000051583A2 (en) 1999-03-02 2000-03-01 Methods and compositions using (+) norcisapride in combination with proton pump inhibitors or h2 receptor antagonists

Publications (1)

Publication Number Publication Date
EA200100936A1 true EA200100936A1 (ru) 2002-10-31

Family

ID=22402463

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100936A EA200100936A1 (ru) 1999-03-02 2000-03-01 Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов

Country Status (23)

Country Link
US (3) US6353005B1 (ru)
EP (1) EP1156852A2 (ru)
JP (1) JP2002538103A (ru)
KR (1) KR20010108298A (ru)
CN (1) CN1364092A (ru)
AR (1) AR037065A1 (ru)
AU (1) AU780579B2 (ru)
BG (1) BG105933A (ru)
BR (1) BR0008687A (ru)
CA (1) CA2362501A1 (ru)
CO (1) CO5150232A1 (ru)
EA (1) EA200100936A1 (ru)
EE (1) EE200100458A (ru)
HR (1) HRP20010635A2 (ru)
HU (1) HUP0200298A3 (ru)
ID (1) ID30445A (ru)
IL (1) IL145162A0 (ru)
NO (1) NO20014230L (ru)
NZ (1) NZ513966A (ru)
PL (1) PL352579A1 (ru)
SK (1) SK12352001A3 (ru)
TR (3) TR200201794T2 (ru)
WO (1) WO2000051583A2 (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6663639B1 (en) 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
US7846180B2 (en) * 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
US6673792B1 (en) * 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
CA2498507A1 (en) * 2002-09-12 2004-03-25 Eli D. Ehrenpreis Monitoring and diagnosis of gastric emptying and gastroparesis
WO2004034973A2 (en) * 2002-10-16 2004-04-29 Warren Stern Method of treating snoring and other obstructive breathing disorders
SE0203410D0 (sv) * 2002-11-18 2002-11-18 Astrazeneca Ab New use
AU2004204825B2 (en) * 2003-01-13 2007-07-19 Dynogen Pharmaceuticals, Inc. Method of treating functional bowel disorders
EP1567163B1 (en) 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Method of treating nausea, vomiting, retching or any combination thereof
WO2004071374A2 (en) * 2003-02-11 2004-08-26 Torrent Pharmaceuticals Limited Once a day orally administered pharmaceutical compositions
WO2004105795A1 (en) * 2003-05-27 2004-12-09 Altana Pharma Ag Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility
WO2005011678A1 (en) * 2003-07-31 2005-02-10 Altana Pharma Ag Method for reducing the volume of gastric refluxate
WO2005021040A2 (en) * 2003-08-29 2005-03-10 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastrointestinal motility disorders
WO2005074931A1 (en) * 2004-01-28 2005-08-18 Altana Pharma Ag Pharmaceutical combinations comprising (s) -pantoprazole
CA2561700A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
MX2007009136A (es) * 2005-01-31 2007-09-06 Novartis Ag Uso de agonista de 5-ht4 para tratar vacio gastrico retrasado que puede inducirse por un inhibidor de bomba de protones.
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists
ES2604943T3 (es) 2007-02-09 2017-03-10 Ocera Therapeutics, Inc. Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
KR101690942B1 (ko) * 2015-03-17 2016-12-29 전남대학교산학협력단 시토크롬 p450 효소전환기술을 이용하여 제조한 오메프라졸 대사체를 이용한 위궤양 치료용 조성물
WO2018215462A1 (en) * 2017-05-22 2018-11-29 Københavns Universitet Cic-2 - the molecular basis of cardiac arrhythmia

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS5914460B2 (ja) 1978-12-27 1984-04-04 相互薬工株式会社 Ｈ↓２受容体「きつ」抗剤シメチジンの製造法
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CA1183847A (en) 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
SE8204879D0 (sv) 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
US4598123A (en) 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
FI90544C (fi) 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
YU45030B (en) 1987-01-23 1991-06-30 Lek Tovarna Farmacevtskih Process for preparing crystalline cimetidine
IT1215344B (it) 1987-01-27 1990-02-08 Dessy S R L Ora Recordati Farm Procedimento per la preparazione di composti ad attivita' anti-ulcera.
JPH0623181B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
JPH0623180B2 (ja) 1987-02-17 1994-03-30 三井石油化学工業株式会社 シアノグアニジン誘導体及びその製造法
US4800162A (en) 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
SE9002043D0 (sv) 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
ES2121984T3 (es) 1991-12-21 1998-12-16 Smithkline Beecham Plc Uso de antagonistas de 5-ht4 para la fabricacion de un medicamento para el tratamiento de la incontinencia urinaria.
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
CA2139638A1 (en) 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
CA2139636A1 (en) 1992-07-07 1994-01-20 Nancy M. Gray Methods of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
JPH08512322A (ja) 1993-07-06 1996-12-24 メルク エンド カンパニー インコーポレーテッド Ｈ▲下２▼拮抗剤−胃腸運動性の薬剤組合せ物
US5502195A (en) 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
US5374730A (en) 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5541335A (en) 1994-07-11 1996-07-30 Torcan Chemical Ltd. Process for preparing nizatidine
US5712293A (en) 1995-06-07 1998-01-27 Sepracor, Inc. Methods for treating gastro-esophageal reflux disease and other disorders associated with the digestive tract using optically pure (-) norcisapride
FR2735475B1 (fr) 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
ATE220543T1 (de) * 1996-04-23 2002-08-15 Janssen Pharmaceutica Nv Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid
NL1003622C2 (nl) 1996-07-17 1998-01-21 Inst Voor Agrotech Onderzoek Lijm op basis van zetmeel.
US6147093A (en) 1996-07-19 2000-11-14 Sepracor Inc. Methods for treating gastroesophageal reflux disease
US5739151A (en) 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
PL190296B1 (pl) 1997-07-11 2005-11-30 Janssen Pharmaceutica Nv Zastosowanie (+)-norcyzaprydu
NZ508824A (en) * 1998-06-15 2003-10-31 Sepracor Inc Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
US6362202B1 (en) * 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) * 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist

Also Published As

Publication number Publication date
KR20010108298A (ko) 2001-12-07
JP2002538103A (ja) 2002-11-12
NZ513966A (en) 2001-09-28
TR200103130T2 (tr) 2002-03-21
TR200201794T2 (tr) 2002-09-23
NO20014230L (no) 2001-11-01
EE200100458A (et) 2002-12-16
ID30445A (id) 2001-12-06
PL352579A1 (en) 2003-08-25
BR0008687A (pt) 2002-01-08
AR037065A1 (es) 2004-10-20
CO5150232A1 (es) 2002-04-29
TR200201795T2 (tr) 2002-09-23
HRP20010635A2 (en) 2002-10-31
EP1156852A2 (en) 2001-11-28
US6353005B1 (en) 2002-03-05
WO2000051583A3 (en) 2001-02-01
WO2000051583A2 (en) 2000-09-08
AU3386200A (en) 2000-09-21
US20030036500A1 (en) 2003-02-20
NO20014230D0 (no) 2001-08-31
CN1364092A (zh) 2002-08-14
AU780579B2 (en) 2005-04-07
CA2362501A1 (en) 2000-09-08
US6552045B2 (en) 2003-04-22
HUP0200298A3 (en) 2002-11-28
HUP0200298A2 (en) 2002-06-29
BG105933A (en) 2002-12-29
SK12352001A3 (sk) 2001-12-03
IL145162A0 (en) 2002-06-30
US20020086880A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
EA200100937A1 (ru) Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
EA200100936A1 (ru) Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов
ATE449081T1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
MA25809A1 (fr) Derives d'arylmethylamine pour usage comme inhibiteurs de tryptase
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
EA200300717A1 (ru) Гетероциклилиндазольные и -азаиндазольные соединения в качестве 5-гидрокситриптамин-6-лигандов
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200300387A1 (ru) Ингибиторы рецептора ep4 для лечения ревматоидного артрита
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
MX2009005604A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.
SE0100172D0 (sv) New inhibitors against galectins
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
ATE371645T1 (de) Naphthalinderivate, die sich an den ep4?rezeptor binden
ATE503755T1 (de) Cgrp-rezeptorantagonisten
MA28909B1 (fr) Quinazolines utiles en tant que modulateurs de canaux ioniques
NO20082894L (no) Metode for behandling av kognitiv dysfunksjon
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
NO20071378L (no) Tiazolo-naftylsyrer.
TW200509949A (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
ATE452884T1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
EA200970127A1 (ru) Модулятор рецепторов глюкокортикостероидов и способы его применения
TW200507855A (en) Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor
DE60321810D1 (de) Neue tricyclische derivate als ltd4 antagonisten